Advanced manufacturing to drive next-gene biomedical research in Australia

Australia has long been a pioneer of biomedical research, but must leverage the capabilities of advanced manufacturing to maintain its competitive advantage.

Dr Peter French, executive director of Sydney-based BCAL Diagnostics and Bioxyne, said: “There is a rich pipeline of gene therapy products currently in the clinic and the gene therapy market is estimated to reach $11 billion by 2025.”

Despite the many companies transitioning into late-stage clinical trials and commercial launch, many lack the capabilities to manufacture gene therapy products on a commercial scale. As a result, it will be a challenge to manufacture sufficient doses to meet potential global demand.